

Martin F Kaiser

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4156662/martin-f-kaiser-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

110
papers

2,950
citations

26
h-index

52
g-index

117
ext. papers

3,931
ext. citations

6.4
avg, IF

4.89
L-index

#	Paper	IF	Citations
110	Functional dissection of inherited non-coding variation influencing multiple myeloma risk.. <i>Nature Communications</i> , 2022 , 13, 151	17.4	0
109	Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment.. <i>Frontiers in Oncology</i> , 2022 , 12, 820768	5.3	0
108	Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102228	2.2	5
107	Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results.. <i>Blood Cancer Journal</i> , 2022 , 12, 52	7	1
106	Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FITNESS (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial. <i>BMJ Open</i> , 2022 , 12, e056147	3	0
105	Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. <i>Haematologica</i> , 2021 , 106, 1957-1967	6.6	6
104	Redefining Non-measurable Multiple Myeloma Using Mass Spectrometry. <i>Blood</i> , 2021 ,	2.2	2
103	Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, Dexamethasone (Dara-CVRd), V-Augmented Autologous Stem Cell Transplant (V-ASCT) and Dara-Vrd Consolidation in Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL) Compared with Myeloma XI/XI+ Trial Treatment for Uhir MM: The UK Optimum/Muknine Trial.	2.2	2
102	Phenotypic High-Risk Disease in the Context of Carfilzomib and Lenalidomide Combination Induction Therapy for Newly Diagnosed Transplant-Eligible Myeloma Patients. <i>Blood</i> , 2021 , 138, 2907-2907	2.2	2
101	The Impact of gain1q on Mutational Structure and Clonal Evolution in a Uniformly Treated High-Risk Series of Patients at First Relapse. <i>Blood</i> , 2021 , 138, 2683-2683	2.2	
100	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. <i>Blood Cancer Journal</i> , 2021 , 11, 192	7	10
99	Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. <i>Leukemia</i> , 2021 , 35, 2043-2053	10.7	10
98	MUK OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia. <i>BMJ Open</i> , 2021 , 11, e046225	3	5
97	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , 2021 , 22, e105-e118	21.7	32
96	Germline variants at SOHLH2 influence multiple myeloma risk. <i>Blood Cancer Journal</i> , 2021 , 11, 76	7	1
95	Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. <i>Blood Advances</i> , 2021 , 5, 2196-2215	7.8	12
94	Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, 667-675	2	1

93	Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK). <i>Haematologica</i> , 2021 , 106, 2694-2706	6.6	2
92	Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients. <i>Haematologica</i> , 2021 , 106, 2754-2758	6.6	9
91	Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma. <i>Lancet Haematology</i> , 2021 , 8, e389-e392	14.6	80
90	Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma. <i>British Journal of Haematology</i> , 2021 , 193, 551-555	4.5	11
89	Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients. <i>Journal of Clinical Pharmacology</i> , 2021 , 61, 614-627	2.9	3
88	Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial. <i>British Journal of Haematology</i> , 2021 , 192, 853-868	4.5	5
87	Characterising spatial heterogeneity of multiple myeloma in high resolution by whole body magnetic resonance imaging: Towards macro-phenotype driven patient management. <i>Magnetic Resonance Imaging</i> , 2021 , 75, 60-64	3.3	3
86	Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. <i>PLoS Medicine</i> , 2021 , 18, e1003454	11.6	4
85	Positive selection as the unifying force for clonal evolution in multiple myeloma. <i>Leukemia</i> , 2021 , 35, 1511-1515	10.7	5
84	Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. <i>Blood Cancer Journal</i> , 2021 , 11, 40	7	11
83	2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. <i>Haematologica</i> , 2021 , 106, 2799-2812	6.6	4
82	Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma. <i>Radiology Imaging Cancer</i> , 2021 , 3, e210048	1.4	1
81	Impact of mitochondrial DNA mutations in multiple myeloma. <i>Blood Cancer Journal</i> , 2020 , 10, 46	7	4
80	Search for multiple myeloma risk factors using Mendelian randomization. <i>Blood Advances</i> , 2020 , 4, 2172-2179	2.879	11
79	Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. <i>British Journal of Haematology</i> , 2020 , 190, e83-e86	4.5	60
78	Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients. <i>Leukemia</i> , 2020 , 34, 3091-3096	10.7	13
77	Reference bias in the Illumina Isaac aligner. <i>Bioinformatics</i> , 2020 , 36, 4671-4672	7.2	
76	Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma. <i>Annals of Hematology</i> , 2020 , 99, 1793-1804	3	3

75	Durable response of multiple myeloma and non-small cell lung cancer with simultaneous, biologically targeted treatment. <i>British Journal of Haematology</i> , 2020 , 189, e1-e3	4.5	1
74	Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2020 , 7, e370-e380	14.6	98
73	Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. <i>Blood</i> , 2020 , 136, 1091-1104	2.2	23
72	High-Throughput Molecular Cancer Cell Line Characterization Using Digital Multiplex Ligation-Dependent Probe Amplification for Improved Standardization of in Vitro Research. <i>Journal of Molecular Diagnostics</i> , 2020 , 22, 1179-1188	5.1	1
71	Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial. <i>Haematologica</i> , 2020 , Online ahead of print,	6.6	4
70	An analysis of the false negative rate of minimal residual disease measurement by multiparameter flow cytometry in multiple myeloma. <i>International Journal of Laboratory Hematology</i> , 2020 , 42, e65-e67	2.5	0
69	The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor. <i>Trials</i> , 2020 , 21, 826	2.8	2
68	An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics. <i>Blood Cancer Journal</i> , 2020 , 10, 101	7	2
67	Improving real-world myeloma patient access to whole body MRI through open-access knowledge sharing: The UK experience. <i>EJHaem</i> , 2020 , 1, 361-363	0.9	2
66	A real-world study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated population of multiple-myeloma patients. <i>British Journal of Haematology</i> , 2020 , 191, 927-930	4.5	3
65	The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. <i>Leukemia</i> , 2020 , 34, 604-612	10.7	32
64	The coordinated action of VCP/p97 and GCN2 regulates cancer cell metabolism and proteostasis during nutrient limitation. <i>Oncogene</i> , 2019 , 38, 3216-3231	9.2	23
63	Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes. <i>Human Genomics</i> , 2019 , 13, 37	6.8	5
62	Detection of avascular necrosis on routine diffusion-weighted whole body MRI in patients with multiple myeloma. <i>British Journal of Radiology</i> , 2019 , 92, 20180822	3.4	3
61	Preclinical toxicology and safety pharmacology of the first-in-class GADD45/MKK7 inhibitor and clinical candidate, DTP3. <i>Toxicology Reports</i> , 2019 , 6, 369-379	4.8	10
60	Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2019 , 9, 23	7	23
59	Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. <i>Haematologica</i> , 2019 , 104, 1440-1450	6.6	39
58	Regions of homozygosity as risk factors for multiple myeloma. <i>Annals of Human Genetics</i> , 2019 , 83, 231-238		1

57	A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. <i>Lancet Haematology, the</i> , 2019 , 6, e154-e166	14.6	44
56	Mutational processes contributing to the development of multiple myeloma. <i>Blood Cancer Journal</i> , 2019 , 9, 60	7	23
55	Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Haematology, the</i> , 2019 , 6, e616-e629	14.6	26
54	Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba. <i>Blood</i> , 2019 , 134, 1906-1906	2.2	4
53	Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update. <i>Blood</i> , 2019 , 134, 1865-1865	2.2	12
52	Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia - Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172). <i>Blood</i> , 2019 , 134, 3162-3162 ²	2.2	12
51	Lenalidomide Maintenance Prolongs Progression-Free Survival and Does Not Impact the Aggressiveness of Clinical Relapse: Data from Long-Term Follow up of the Myeloma XI Trial. <i>Blood</i> , 2019 , 134, 1889-1889	2.2	2
50	Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 8005-8005	2.2	12
49	Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). <i>Radiology</i> , 2019 , 291, 5-13	20.5	117
48	Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 57-73	21.7	154
47	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019 , 393, 253-264	40	131
46	Clinical proof of concept for a safe and effective NF-B-targeting strategy in multiple myeloma. <i>British Journal of Haematology</i> , 2019 , 185, 588-592	4.5	10
45	Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms. <i>Leukemia</i> , 2018 , 32, 2459-2470	10.7	43
44	Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. <i>Leukemia</i> , 2018 , 32, 1727-1738	10.7	27
43	Progression Free Survival below 12 Months Following Stem Cell Transplant Is a Hallmark of High-Risk Myeloma Which Is Associated with Inferior Overall Survival Data from the Ukmrc Myeloma XI Trial. <i>Blood</i> , 2018 , 132, 122-122	2.2	3
42	Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial. <i>Blood</i> , 2018 , 132, 321-321	2.2	7
41	A phase 1, open-label, multicenter, non-randomized study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD4573, a potent and selective CDK9 inhibitor, in subjects with relapsed or refractory hematological malignancies.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS7588-TPS7588	2.2	2
40	Update on Clinical Safety and Efficacy of the Novel Oral Dual RAF/MEK Inhibitor RO5126766 (CH5127566) in RAS-mutant Multiple Myeloma. <i>Blood</i> , 2018 , 132, 3237-3237	2.2	

39	Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials. <i>Blood</i> , 2018 , 132, 2000-2000	2.2	
38	Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. <i>Blood Cancer Journal</i> , 2018 , 9, 1	7	18
37	Apparent diffusion coefficient of vertebral haemangiomas allows differentiation from malignant focal deposits in whole-body diffusion-weighted MRI. <i>European Radiology</i> , 2018 , 28, 1687-1691	8	21
36	Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring Mutations: A Cohort of the Histology-Independent VE-BASKET Study. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6	14
35	The genomic landscape of plasma cells in systemic light chain amyloidosis. <i>Blood</i> , 2018 , 132, 2775-2777	2.2	10
34	Whole-Body Imaging in Multiple Myeloma. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2018 , 26, 509-525	1.6	12
33	Subclonal copy number is associated with prognosis in multiple myeloma. <i>Blood</i> , 2018 , 132, 2465-2469	2.2	21
32	Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. <i>Nature Communications</i> , 2018 , 9, 3707	17.4	57
31	A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis. <i>Blood Advances</i> , 2018 , 2, 2400-2411	7.8	3
30	Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci. <i>Scientific Reports</i> , 2017 , 7, 41071	4.9	27
29	Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. <i>European Journal of Haematology</i> , 2017 , 99, 199-206	3.8	15
28	Constitutional mutation in CDKN2A is associated with long term survivorship in multiple myeloma: a case report. <i>BMC Cancer</i> , 2017 , 17, 718	4.8	11
27	Neutral tumor evolution in myeloma is associated with poor prognosis. <i>Blood</i> , 2017 , 130, 1639-1643	2.2	14
26	Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism. <i>Cell Reports</i> , 2017 , 20, 2556-2564	10.6	15
25	The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience. <i>Leukemia and Lymphoma</i> , 2017 , 58, 494-497	1.9	12
24	Results from the biomarker-driven basket trial of RO5126766 (CH5127566), a potent RAF/MEK inhibitor, in RAS- or RAF-mutated malignancies including multiple myeloma. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2506-2506	2.2	18
23	Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression. <i>Nature Communications</i> , 2016 , 7, 13656	17.4	26
22	Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. <i>Nature Communications</i> , 2016 , 7, 12050	17.4	101

21	The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma. <i>BMC Hematology</i> , 2016 , 16, 14	2.5	7
20	Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma. <i>Nature Communications</i> , 2016 , 7, 10290	17.4	26
19	A Phase I Dose-Escalation Study of the Class 1 Selective Histone Deacetylase Inhibitor CHR-3996 in Combination with Tosedostat for Patients with Relapsed, Refractory Multiple Myeloma: Results of the Muk Three Trial. <i>Blood</i> , 2016 , 128, 3321-3321	2.2	3
18	Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. <i>Blood</i> , 2016 , 128, 497-503	2.2	117
17	APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. <i>Nature Communications</i> , 2015 , 6, 6997	17.4	176
16	Whole body diffusion weighted MRI--a new view of myeloma. <i>British Journal of Haematology</i> , 2015 , 171, 29-37	4.5	63
15	Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3911-20	2.2	348
14	A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma. <i>Genes Chromosomes and Cancer</i> , 2015 , 54, 91-8	5	26
13	Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma. <i>Scientific Reports</i> , 2015 , 5, 12473	4.9	16
12	Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); A Report of Second Primary Malignancy (SPM) Rates and the Importance of Review of Reported Cases. <i>Blood</i> , 2015 , 126, 1847-1847	2.2	1
11	Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAFV600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study. <i>Blood</i> , 2015 , 126, 4263-4263	2.2	9
10	Molecular Subtyping and Risk Stratification for the Classification of Myeloma. <i>Blood</i> , 2015 , 126, 4173-4173	2.2	3
9	Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. <i>Blood</i> , 2014 , 123, 3414-9	2.2	51
8	Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment. <i>Blood</i> , 2014 , 124, 2467-8	2.2	45
7	Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. <i>Leukemia</i> , 2014 , 28, 384-390	10.7	202
6	A novel functional role for MMSET in RNA processing based on the link between the REIIBP isoform and its interaction with the SMN complex. <i>PLoS ONE</i> , 2014 , 9, e99493	3.7	4
5	The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. <i>Nature Genetics</i> , 2013 , 45, 522-525	36.3	79
4	Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. <i>Blood</i> , 2013 , 122, 219-26	2.2	128

- 3 Single-Cell Genetic Analysis Reveals The Genetic Composition Of Founder Clones, Phylogenetic Patterns Of Branching and Parallel Evolution, and Clonal Fluctuations Following Patient Treatment In Multiple Myeloma. *Blood*, **2013**, 122, 398-398 2.2
- 2 Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib. *Clinical Lymphoma, Myeloma and Leukemia*, **2010**, 10, 134-7 2 32
- 1 Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. *Blood Cancer Discovery*, OF1-OF12 7 2